Media coverage about Patheon (NYSE:PTHN) has been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Patheon earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.7916346284696 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Separately, BidaskClub downgraded shares of Patheon from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $33.60.
Patheon has a 1-year low of $23.72 and a 1-year high of $35.13. The company has a debt-to-equity ratio of -7.33, a quick ratio of 0.91 and a current ratio of 1.65. The stock has a market cap of $5,080.00 and a PE ratio of 45.43.
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.